← 返回

接受过继性细胞治疗的实体瘤患者的感染

英文原题:Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.

查看英文原题

Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.

PubMed 2025/02/22(内容时间) Transplant Cell Ther Q1 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过继性细胞治疗(ACT)是一种日益广泛应用的恶性肿瘤治疗方法。虽然ACT的感染性并发症在血液系统恶性肿瘤患者中已有充分描述,但关于实体瘤患者感染流行病学的数据有限。

本研究旨在描述接受ACT治疗的成人实体瘤患者在最初180天内发生的感染流行病学,并确定使这些患者易发生感染的危险因素。收集了2014年8月至2021年11月在Memorial Sloan Kettering Cancer Center接受ACT的132例成人实体瘤患者的数据。感染记录从ACT输注当天至输注后第180天。

总体而言,132例患者中有28例(21.2%)在ACT后最初30天内发生了33次感染,131例存活患者中有17例(13%)在第31天至第180天之间被诊断出24次感染。感染相关死亡率较低。大多数感染为细菌性。虽然在单变量分析中,男性、年龄较大、ACT输注时的美国东部肿瘤协作组(ECOG)体能状态(PS)、接受tocilizumab以及接受tocilizumab治疗的细胞因子释放综合征与首次感染时间较短相关,但在多变量分析中,只有ECOG PS和接受tocilizumab仍为独立危险因素。实体瘤患者在接受ACT后发生早期或晚期感染的比例低于B细胞恶性肿瘤患者在接受CAR-T 细胞治疗后所报告的比例。观察到的大多数感染主要为细菌性,感染相关死亡率较低;病毒和真菌感染的发生率较低。基于感染相对于中性粒细胞减少症的低发生频率和时间分布,抗菌和抗真菌预防治疗不太可能获益。ECOG PS 2 和接受托珠单抗被确定为 ACT 后感染的显著预测因素,可能提示个体处于易感感染的衰弱状态。需要进一步研究以排除混杂因素,从而更好地识别感染的危险因素。

展开英文摘要原文

Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are available on the epidemiology of infections in patients with solid tumors.

The purpose of this study was to describe the epidemiology of infections occurring within the first 180 days in adult patients with solid tumors treated with ACT and to identify risk factors predisposing these patients to infection. Data on 132 adult patients with solid tumors undergoing ACT between August 2014 and November 2021 at Memorial Sloan Kettering Cancer Center were collected. Infections were documented from the day of ACT infusion through day 180 postinfusion.

Overall, 28 of 132 patients (21. 2%) experienced 33 infections within the first 30 days of ACT, and 17 of 131 surviving patients (13%) were diagnosed with 24 infections between day 31 and day 180. Infection-related mortality was low. The majority of infections were bacterial. While male gender, older age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) at time of ACT infusion, tocilizumab receipt, and cytokine release syndrome treated with tocilizumab were associated with shorter time to first infection on univariable analysis, only ECOG PS and tocilizumab receipt remained independent risk factors in the multivariable analysis.

The proportion of patients with solid tumors experiencing early or late infections after ACT was lower compared to that reported among patients with B cell malignancies after chimeric antigen receptor T cell therapy. Most observed infections were primarily bacterial with low infection-related mortality; the incidence of viral and fungal infections was low.

Based on the low frequency and timing of infections relative to neutropenia, antibacterial and antifungal prophylaxis are not likely to be beneficial. ECOG PS 2 and tocilizumab receipt were identified as significant predictors for infection after ACT, likely signaling an individual's debilitated state that predisposes to infection. Additional work to parse out confounders is needed to better identify risk factors for infection.

论文信息

作者
Avutu V、Algazaq JN、Seier K、Desir-Camille R、Qin LX、Babatunde O、Adusumilli PS、Klebanoff CA
单位
Department of Medicine, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address: avutuv@mskcc.org.United States
期刊
Transplantation and cellular therapy2026 Sep
原文标识
PubMed 39993596 · DOI 10.1016/j.jtct.2025.02.017